Physician profile
Meredith E Gates
NPI 1003554031
$2,455.16
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $554 · 2024: $1,901.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,455.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,455.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medline Industries Lp | $554.56 | 2023-2024 | Medline Industries, INC. |
| Polynovo North America LLC | $549.87 | 2024 | Novosorb Btm |
| Avita Medical Americas, LLC | $452.28 | 2024 | |
| Polymedics Innovations INC. | $268.61 | 2023-2024 | |
| Vericel Corporation | $153.21 | 2023-2024 | Epicel (Cultured Epidermal Autografts), Nexobrid |
| La Jolla Pharmaceutical Company | $150.72 | 2024 | Xacduro, Giapreza, Xerava |
| Abbvie INC. | $117.12 | 2024 | |
| Integra Lifesciences Corporation | $65.57 | 2023 | Integra, Primatrix, Integra Dermal Regeneration Template |
| Shionogi INC | $38.74 | 2024 | Fetroja |
| Acera Surgical, INC. | $35.38 | 2023-2024 | Restrata Wound Matrix |
| Smith+Nephew, INC. | $22.30 | 2024 | Oasis, Collagenase Santyl, Versajet |
| Solventum Corporation | $21.71 | 2024 | V.A.C.Ulta |
| Medela LLC | $13.27 | 2023 | Invia Motion Endure |
| Kerecis Limited | $11.82 | 2023-2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Meredith Gates listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.